Media Coverage

Grants Help Propel Glaucoma, Macular Degeneration Research

Three Vanderbilt University Medical Center faculty members have been awarded grants from the American Health Assistance Foundation to support their research on glaucoma and macular degeneration — the two leading causes of irreversible blindness in the world.

Vanderbilt Eye Institute researchers received three of the 21 grants given by the organization tasked with funding breakthrough research on age-related vision diseases.

The awards are $100,000 each.

John Kuchtey, Ph.D., research assistant professor of Ophthalmology and Visual Sciences at VEI, and colleagues are studying ways to detect the genes causing inherited glaucoma in newborns and infants.

Families previously screened and found negative for mutations in known primary congenital glaucoma (PCG) genes will be studied to identify the disease-causing mutations in hopes of discovering new glaucoma genes.

“The hallmark symptom of PCG is severely elevated eye pressure,” said Kuchtey. “Identification of a new glaucoma gene involved in increased eye pressure due to insufficient drainage of aqueous humor will improve the basic understanding of glaucoma, which may lead to more effective diagnosis and treatment of glaucoma for patients of all ages.”

Kuchtey was also named the AHAF 2012 Thomas R. Lee Award recipient, given for outstanding research in glaucoma.

“I hope I can live up to the honor and produce some interesting and useful science,” Kuchtey said.

Milam Brantley Jr., M.D., Ph.D., assistant professor of Ophthalmology and Visual Sciences and director of the Initiative for Ocular Pharmacogenomics at VEI, is studying the environmental risks for age-related macular degeneration (AMD).

Brantley and his colleagues have developed a comprehensive method for assessing risk using a cutting-edge technique called metabolomics. The team is able to measure the levels of thousands of metabolic markers in the blood to identify environmental influences on AMD risk factors.

“Determining the combination of metabolic and genetic factors associated with AMD will lead to a better understanding of the disease, and ultimately may lead to personalized clinical care,” said Brantley. “Further, a blood test combining genetics and metabolism could be developed to predict an individual’s risk for developing AMD and allow more timely treatment to prevent AMD-related vision loss.”

Ashwath Jayagopal, Ph.D., assistant professor of Ophthalmology and Visual Sciences at VEI, and colleagues are working on developing nanotechnology-based approaches for imaging critical biomarkers of early wet AMD.

“This technique could introduce a new clinical approach for enhancing diagnostic capabilities in the management of AMD,” said Jayagopal. “Clinicians may be able to detect wet AMD at a point that enables therapies to be administered to the patient in a more timely fashion, better preserving vision.

“Furthermore, the approach could be used to monitor disease progression and determine whether a course of therapy is effective in treating the patient.”

Read the original article here.

This content was first posted on: September 27, 2012

The information provided in this section is a public service of BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.